JAMA Network Open Impact Factor

JAMA Network Open is young, launched in 2018, so its trend table should not be read like a century-old general medicine title. The useful trend is not a long pre-2018 history. It is the post-launch normalization from pandemic-era citation spikes into the current open-access general medicine tier.

Source limitation: this table is a decision-support guardrail, not a formal historical JIF table. The current 11.7 value is the decision number. Older exact year rows should be verified in Journal Citation Reports before they are cited formally.

The useful rank read is conservative: JAMA Network Open is a Q1 general/internal medicine journal, but the exact JCR rank and percentile should be checked inside Journal Citation Reports before being used in formal institutional documents.

An 11.7 JIF confirms that JAMA Network Open is one of the strongest fully open-access general medicine venues. It is not a low-stakes fallback after JAMA, and it is not just a large-volume repository. The official author page describes the journal as an international, peer-reviewed, open-access, general medical journal for clinical care, health policy, global health, health care innovation, public health, and related fields.

For authors, the number should change three decisions. First, JAMA Network Open can be a rational first-choice target when the manuscript needs immediate open access and a broad clinical audience. Second, the citation tier does not remove the need for JAMA-family routing discipline. A paper that is excellent but mostly oncology, cardiology, neurology, pediatrics, psychiatry, or surgery may be cleaner at a JAMA specialty journal. Third, the 12% acceptance rate means the open-access model should not be confused with easy acceptance.

The reach signals matter because the page is not only a bibliometric lookup. JAMA Network Open reports more than 39 million annual article views and downloads, broad media reach, daily online publication, and indexing in PubMed/MEDLINE, PubMed Central, Scopus, Science Citation Index Expanded, DOAJ, Google Scholar, and other systems. Those signals make the journal attractive for studies with public-health, clinical-practice, health-policy, or health-services relevance.

In our pre-submission review work for JAMA Network Open-targeted manuscripts, the impact factor usually answers only the first question. The harder question is whether the paper belongs in this exact part of the JAMA Network. Three specific failure patterns recur when authors use the 11.7 number as a target signal.

Manusights has reviewed 74+ manuscripts targeting JAMA-family journals. In our analysis of JAMA Network Open-targeted submissions, the recurring mistake across those manuscripts is treating the journal as "JAMA but easier and open access" instead of proving broad clinical or public-health fit on its own terms. In practice: the 11.7 JIF helps authors benchmark the target, but the abstract, Key Points, reporting checklist, and route-choice logic decide whether the manuscript belongs here.

Broad clinical consequence is assumed rather than stated. Authors often choose JAMA Network Open because the JIF is strong and the journal is open access, then leave the abstract framed for a specialist. The fix is to make the Key Points and conclusion readable to a general clinical, health-policy, or public-health audience. If a non-specialist has to infer the practical consequence, the paper looks misrouted.

JAMA-family routing is chosen from cost or speed alone. JAMA Network Open lists fast median decisions and a gold open-access model, but those are not substitutes for fit. A specialist oncology, cardiology, neurology, or psychiatry manuscript can be more credible at the relevant JAMA specialty journal even if JAMA Network Open is faster or fully open access. The cover letter should explain why the broader JAMA Network Open audience is the right reader.

Reporting quality is weaker than the citation ambition. A high JIF target increases scrutiny of the reporting package. We see papers with promising results but incomplete CONSORT, STROBE, PRISMA, STARD, or prediction-model reporting support. The issue is not only administrative. If the reporting package is thin, the manuscript does not support the public claim it wants JAMA Network Open to amplify.

These patterns show up first in the abstract, Key Points, statistical methods, limitations paragraph, and cover-letter route choice. The strongest JAMA Network Open submissions make the public-health or clinical-practice consequence explicit before methodology detail. They also show that the reporting package can carry the breadth of the claim, rather than relying on the journal's 11.7 JIF to create significance after upload.

For authors choosing between JAMA Network Open, PLOS Medicine, BMC Medicine, BMJ Open, and a JAMA specialty journal, the key test is whether the same conclusion would matter to clinicians, health-system leaders, and policy readers outside the immediate specialty. If the answer is no, the manuscript may still be publishable, but the 11.7 JIF is probably pulling the target list higher than the paper's current audience fit.

Before upload, a JAMA Network Open journal-fit check can test whether the abstract, study design, reporting package, and route choice support the target.

JAMA Network Open at 11.7 is a strong open-access general medicine target. The current number should replace stale 9.7 copy when authors search for the latest metric after the June 2026 JCR release. But the JIF should not be the whole decision. The best JAMA Network Open submissions connect a credible clinical or health-policy result to a broad JAMA Network readership, with complete reporting and a clear route choice.

If your manuscript is broad, clinically relevant, and ready for a gold open-access JAMA Network audience, 11.7 supports the target. If the paper is narrow, mainly specialist-facing, or still missing reporting support, a lower-JIF specialty journal may be a better strategic choice.